MONTPELLIER, France, Feb. 02, 2016 -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce continued commercial expansion with two new sales of its ROSA™ Brain robot in the U.S., to Brigham and Women’s Hospital and the University of Colorado Medical Center.
Brigham and Women's Hospital, located in Boston, Massachusetts, is one of America’s most prestigious hospital centers, and has been recognized as one of the 10 best American hospitals by U.S. News & World Report.
The University of Colorado Medical Center in Aurora, Colorado is a renowned institution, particularly for neurology and neurosurgery. In 2015, it was ranked as the best hospital in the state of Colorado by U.S. News & World Report.
Bertin Nahum, CEO and Founder of Medtech, commented, “We are delighted with the ongoing increase of ROSA™ robots sold in the U.S., which is a significant market for our Company. These sales to prestigious institutions demonstrate the growing interest in our ROSA™ technology and the important role it can play supporting leading neurosurgeons and their patients.”
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 [email protected] PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 [email protected] Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected]


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Instagram Outage Disrupts Thousands of U.S. Users
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



